Polycystic Ovary Syndrome Clinical Trial
Official title:
Evaluation of the Activity of Chronic Inflammation and Its Impact on Metabolic and Hormonal Parameters in Various PCOS Phenotypes
Chronic inflammation in polycystic ovary syndrome (PCOS) may be the result of dysregulation of cytokine production (due to insulin resistance, excess visceral fat and hyperandrogenemia), i.e., overproduction of pro-inflammatory factors (e.g. TNF, IL-1, IL-6) in relation to anti-inflammatory ones (IL-10). This condition may be an important link between obesity and insulin resistance, which is crucial in the etiopathogenesis of the syndrome. However, it is not known whether it results from the tendency to accumulate adipose tissue or is a feature of the syndrome itself. There is no data indicating the relationship between chronic inflammation and the severity of metabolic disorders and the value of ovarian reserve in women with various PCOS phenotypes.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | June 30, 2024 |
Est. primary completion date | June 1, 2024 |
Accepts healthy volunteers | |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - age 18-45 years - PCOS syndrome confirmed by the Rotterdam criteria Exclusion Criteria: - absence of at least one ovary - diagnosed and/or treated other metabolic disease - diagnosed and/or treated other endocrine disease |
Country | Name | City | State |
---|---|---|---|
Poland | Jagiellonian University Medical College | Krakow |
Lead Sponsor | Collaborator |
---|---|
Jagiellonian University |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Values of inflammation parameters - leukocytosis in peripheral blood in the four PCOS phenotypes | Measurement and comparison of leukocyte count (n/µL) in peripheral blood in the four PCOS phenotypes | up to 3 months | |
Primary | Values of inflammation parameters - C-reactive protein (CRP) in peripheral blood in the four PCOS phenotypes | Measurement and comparison of concentrations of CRP (mg/l) in peripheral blood in the four PCOS phenotypes | up to 3 months | |
Primary | Values of inflammation parameters - IL-1 in peripheral blood in the four PCOS phenotypes | Measurement and comparison of concentrations of IL-1 (pg/ml) in peripheral blood in the four PCOS phenotypes | up to 3 months | |
Primary | Values of inflammation parameters - IL-6 in peripheral blood in the four PCOS phenotypes | Measurement and comparison of concentrations of IL-6 (pg/ml) in peripheral blood in the four PCOS phenotypes | up to 3 months | |
Primary | Values of inflammation parameters - IL-10 in peripheral blood in the four PCOS phenotypes | Measurement and comparison of concentrations of IL-10 (pg/ml) in peripheral blood in the four PCOS phenotypes | up to 3 months | |
Primary | Values of inflammation parameters - TNF-alpha in peripheral blood in the four PCOS phenotypes | Measurement and comparison of concentrations of TNF-alpha (pg/ml) in peripheral blood in the four PCOS phenotypes | up to 3 months | |
Secondary | Correlation between the HOMA-IR value and the parameters of inflammation - leukocytosis in the four PCOS phenotypes | Evaluation of the correlation between the HOMA-IR value and inflammatory parameters: leukocyte count (n/µL) | up to 3 months | |
Secondary | Correlation between the homeostatic model assessment for insulin resistance (HOMA-IR) value and the parameters of inflammation - CRP in the four PCOS phenotypes | Evaluation of the correlation between the HOMA-IR value and inflammatory parameters: CRP (mg/l) | up to 3 months | |
Secondary | Correlation between the HOMA-IR value and the parameters of inflammation - il-1 in the four PCOS phenotypes | Evaluation of the correlation between the HOMA-IR and inflammatory parameters: il-1 (pg/ml) | up to 3 months | |
Secondary | Correlation between the HOMA-IR value and the parameters of inflammation - il-6 in the four PCOS phenotypes | Evaluation of the correlation between HOMA-IR value and inflammatory parameters: il-6 (pg/ml) | up to 3 months | |
Secondary | Correlation between the concentration of HOMA-IR and the parameters of inflammation - il-10 in in the four PCOS phenotypes | Evaluation of the correlation between the concentration of HOMA-IR and inflammatory parameters: il-10 (pg/ml) | up to 3 months | |
Secondary | Correlation between the HOMA-IR value and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes | Evaluation of the correlation between the HOMA-IR value and inflammatory parameters: TNF-alpha (pg/ml) | up to 3 months | |
Secondary | Correlation between the body mass index (BMI) value and the parameters of inflammation - leukocytosis in the four PCOS phenotypes | Evaluation of the correlation between the BMI value and inflammatory parameters: leukocyte count (n/µL) | up to 3 months | |
Secondary | Correlation between the BMI value and the parameters of inflammation - CRP in the four PCOS phenotypes | Evaluation of the correlation between the BMI value and inflammatory parameters: CRP (mg/l) | up to 3 months | |
Secondary | Correlation between the BMI value and the parameters of inflammation - il-1 in the four PCOS phenotypes | Evaluation of the correlation between the BMI and inflammatory parameters: il-1 (pg/ml) | up to 3 months | |
Secondary | Correlation between the BMI value and the parameters of inflammation - il-6 in the four PCOS phenotypes | Evaluation of the correlation between BMI value and inflammatory parameters: il-6 (pg/ml) | up to 3 months | |
Secondary | Correlation between the concentration of BMI and the parameters of inflammation - il-10 in in the four PCOS phenotypes | Evaluation of the correlation between BMI value and inflammatory parameters: il-10 (pg/ml) | up to 3 months | |
Secondary | Correlation between the BMI value and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes | Evaluation of the correlation between the BMI value and inflammatory parameters: TNF-alpha (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of aspartate aminotransferase (AST) concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes | Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: leukocyte count (n/µL) | up to 3 months | |
Secondary | Correlation between the value of AST concentration and the parameters of inflammation - CRP in the four PCOS phenotypes | Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: CRP (mg/l) | up to 3 months | |
Secondary | Correlation between the value of AST concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes | Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: il-1 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of AST concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes | Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: il-6 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of AST concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes | Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: il-10 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of AST concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes | Evaluation of the correlation between AST concentration (U/l) and inflammatory parameters: TNF-alpha (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of alanine aminotransferase (ALT) concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes | Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: leukocyte count (n/µL) | up to 3 months | |
Secondary | Correlation between the value of ALT concentration and the parameters of inflammation - CRP in the four PCOS phenotypes | Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: CRP (mg/l) | up to 3 months | |
Secondary | Correlation between the value of ALT concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes | Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: il-1 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of ALT concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes | Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: il-6 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of ALT concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes | Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: il-10 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of ALT concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes | Evaluation of the correlation between ALT concentration (U/l) and inflammatory parameters: TNF-alpha (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of total bilirubin concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes | Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: leukocyte count (n/µL) | up to 3 months | |
Secondary | Correlation between the value of total bilirubin concentration and the parameters of inflammation - CRP in the four PCOS phenotypes | Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: CRP (mg/l) | up to 3 months | |
Secondary | Correlation between the value of total bilirubin concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes | Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: il-1 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of total bilirubin concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes | Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: il-6 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of total bilirubin concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes | Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: il-10 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of total bilirubin concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes | Evaluation of the correlation between total bilirubin concentration (mg/dl) and inflammatory parameters: TNF-alpha (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of total cholesterol concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes | Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: leukocyte count (n/µL) | up to 3 months | |
Secondary | Correlation between the value of total cholesterol concentration and the parameters of inflammation - CRP in the four PCOS phenotypes | Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: CRP (mg/l) | up to 3 months | |
Secondary | Correlation between the value of total cholesterol concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes | Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: il-1 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of total cholesterol concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes | Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: il-6 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of total cholesterol concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes | Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: il-10 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of total cholesterol concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes | Evaluation of the correlation between total cholesterol concentration (mg/dl) and inflammatory parameters: TNF-alpha (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of triglycerides concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes | Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: leukocyte count (n/µL) | up to 3 months | |
Secondary | Correlation between the value of triglycerides concentration and the parameters of inflammation - CRP in the four PCOS phenotypes | Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: CRP (mg/l) | up to 3 months | |
Secondary | Correlation between the value of triglycerides concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes | Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: il-1 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of triglycerides concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes | Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: il-6 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of triglycerides concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes | Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: il-10 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of triglycerides concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes | Evaluation of the correlation between triglycerides concentration (mg/dl) and inflammatory parameters: TNF-alpha (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of Anti-Müllerian hormone (AMH) concentration and the parameters of inflammation - leukocytosis in the four PCOS phenotypes | Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: leukocyte count (n/µL) | up to 3 months | |
Secondary | Correlation between the value of AMH concentration and the parameters of inflammation - CRP in the four PCOS phenotypes | Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: CRP (mg/l) | up to 3 months | |
Secondary | Correlation between the value of AMH concentration and the parameters of inflammation - il-1 in the four PCOS phenotypes | Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: il-1 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of AMH concentration and the parameters of inflammation - il-6 in the four PCOS phenotypes | Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: il-6 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of AMH concentration and the parameters of inflammation - il-10 in in the four PCOS phenotypes | Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: il-10 (pg/ml) | up to 3 months | |
Secondary | Correlation between the value of AMH concentration and the parameters of inflammation - TNF-alpha in the four PCOS phenotypes | Evaluation of the correlation between AMH concentration (pmol/l) and inflammatory parameters: TNF-alpha (pg/ml) | up to 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03142633 -
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
|
||
Completed |
NCT06158932 -
A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04932070 -
Berberine and Polycystic Ovary Syndrome
|
N/A | |
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT03480022 -
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
|
Phase 3 | |
Active, not recruiting |
NCT03043924 -
Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)
|
N/A | |
Completed |
NCT05246306 -
Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
|
||
Completed |
NCT05981742 -
Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS
|
Phase 2 | |
Completed |
NCT05702957 -
Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT05029492 -
Effect of Visceral Manipulation on PCOS
|
N/A | |
Completed |
NCT02924025 -
Motivational Interviewing as an Intervention for PCOS
|
N/A | |
Not yet recruiting |
NCT02255578 -
Endobarrier Treatment in Women With PCOS
|
Phase 3 | |
Completed |
NCT02098668 -
Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON
|
N/A | |
Not yet recruiting |
NCT00883259 -
Metformin and Gestational Diabetes in High-risk Patients: a RCTs
|
Phase 4 | |
Withdrawn |
NCT01638988 -
Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin
|
Phase 3 | |
Completed |
NCT01462864 -
Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome
|
N/A | |
Recruiting |
NCT01431352 -
Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS)
|
N/A | |
Completed |
NCT00989781 -
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
|
N/A |